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InﬂammationChemokine receptors on leukocytes mediate the recruitment and accumulation of these cells within
affected joints in chronic inﬂammatory diseases such as rheumatoid arthritis (RA). Identiﬁcation of
involved receptors offers potential for development of therapeutic interventions. The objective of this
study was to investigate the expression of orphan receptor GPR15/BOB in the synovium of RA and
non-RA patients and in peripheral blood of RA patients and healthy donors.
GPR15/BOB protein and messenger RNA expression were examined in RA and non-RA synovium by
immunoﬂuorescence and reverse-transcription polymerase chain reaction (RT-PCR) respectively.
GPR15/BOB expression on peripheral blood leukocytes was analysed by ﬂow cytometry and GPR15/
BOB messenger RNA was examined in peripheral blood monocytes by RT-PCR.
GPR15/BOB protein was observed in CD68+ and CD14+ macrophages in synovia, with greater expres-
sion in RA synovia. GPR15/BOB protein was expressed in all patient synovia whereas in non-RA synovia
expression was low or absent. Similarly GPR15/BOB messenger RNA was detected in all RA and a minority
of non-RA synovia. GPR15/BOB protein was expressed on peripheral blood leukocytes from RA and
healthy individuals with increased expression by monocytes and neutrophils in RA. GPR15/BOB messen-
ger RNA expression was conﬁrmed in peripheral blood monocytes.
In conclusion GPR15/BOB is expressed by macrophages in synovial tissue and on monocytes and neu-
trophils in peripheral blood, and expression is up-regulated in RA patients compared to non-RA controls.
This orphan receptor on monocytes/macrophages and neutrophils may play a role in RA pathophysiology.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
In rheumatoid arthritis (RA) the synovial membrane undergoes
inﬁltration by monocytes/macrophages, T cells and B cells, and
neutrophils accumulate in the synovial ﬂuid, and these cells are
centrally involved in disease mechanisms [1–4]. GPR15/BOB is an
orphan chemokine receptor whose natural ligand is unknown. It
was found by expression cloning of simian immunodeﬁciency virus
(SIV) receptors which isolated two genes encoding G protein-cou-
pled receptors (GPCRs). These proteins were named Bonzo
(STRL33/CXCR6) and BOB (brother of Bonzo) and presented simi-
larities to chemokine receptors [5]. BOB is 360 amino acids in size
and is identical to the previously cloned orphan receptor, GPR15[6]. GPR15/BOB exhibits the primary structure of a 7-transmem-
brane domain protein and shares sequence identity with regions
of the angiotensin II receptor and GPCRs CXCR2, CXCR4, CCR5,
DEZ (chemerin receptor), GPR1 and APJ (apelin receptor) [6,7].
GPR15/BOB and CCR5 share a sequence of three tyrosine residues
in the amino-terminal region, which if altered in CCR5, results in
decreased efﬁciency of infection by SIV and macrophage-tropic hu-
man immunodeﬁciency virus (HIV)-1 strains [7].
GPR15/BOB is a co-receptor for simian immunodeﬁciency virus
(SIV) and human immunodeﬁciency virus types 1 and 2 (HIV-1 and
HIV-2) [7,8]. The majority of HIV-2 envelope glycoproteins and a
minority of HIV-1 envelope glycoproteins are able to use GPR15/
BOB as a co-receptor, but inefﬁciently when compared to CCR5
or CXCR4 [5,9,10]. SIV uses GPR15/BOB to infect cell lines transfec-
ted to express the receptor. GPR15/BOB is expressed on a number
of human B and T cell lines including the T/B cell hybrid cell line
CEMx174. GPR15/BOB is required for SIV infection of CEMx174
[5,9,11]. It is therefore probable that GPR15/BOB does not function
as an efﬁcient co-receptor for HIV-1 in vivo and is more likely to
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be involved in HIV enteropathy, a condition whereby patients with
HIV infection develop malabsorption and increased intestinal per-
meability with diarrhoea [12,13].
GPR15/BOB is highly expressed on the surface of neutrophils
from Chinese rhesus macaques and its ligation during early SIV
infection induces neutrophil death and is associated with neutro-
penia and disease progression [14]. Increased neutrophil apoptosis
and neutropenia have also been reported in HIV patients [14].
GPR15/BOB mRNA was detected in spleen, at high levels in co-
lon and low levels in small intestine and thymus [5]. GPR15/BOB
protein has been detected on subsets of CD4+ and CD8+ T cells
and also CD19+ B cells from healthy human peripheral blood
mononuclear cell preparations [11]; it is also expressed by human
alveolar macrophages [7]. GPR15/BOB protein has been demon-
strated in small intestinal and colonic mucosa, prostate, testis
and liver. In the small intestine it was expressed by lymphocytes
and abundant expression was observed on the basolateral surfaces
of the epithelium [12,15]. Recently GPR15/BOB was shown to reg-
ulate the homing of T cells, particularly FOXP3(+) regulatory T cells
(Tregs), to the large intestine lamina propria. This indicates the role
for the receptor in leukocyte recruitment in inﬂammation [16].
However, GPR15/BOB expression in chronic inﬂammatory disease
has not been studied.
In a microarray study we found evidence for expression of
GPR15/BOB mRNA in human RA synovium [17]. In the present
study we have substantiated and continued this initial work and
examined the mRNA expression and cellular source of GPR15/
BOB in synovium by RT-PCR and immunoﬂuorescence microscopy.
We have further examined the expression of GPR15/BOB in RA
peripheral blood. This study shows expression of GPR15/BOB in a
chronic inﬂammatory autoimmune disease with up-regulation in
RA pathology.2. Material and methods
2.1. Ethics
Ethical approval for the study was obtained from Shropshire
and Staffordshire Local Research Ethics Committee (reference 03/
72/RJH and 03/73/RJH) and patients provided written informed
consent.2.2. Synovial tissue
Synovial tissue samples were obtained from RA patients under-
going knee replacement surgery at the Robert Jones & Agnes Hunt
Orthopaedic Hospital in Oswestry. RA patients (n = 13; 2 male and
11 female; average age 66.8 years, range 33–79 years; disease
duration ranging from 3 to 39 years) were taking disease-modify-
ing drugs (methotrexate, etanercept, hydroxychloroquine or
leﬂunomide) or steroids, had raised erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) and fulﬁlled the American Col-
lege of Rheumatology criteria for classiﬁcation of the disease [18].
Control synovia were from non-RA patients (n = 9; 6 male and 3
female; average age 54.8 years, range 41–58 years) who had no
history of RA, were medication free and undergoing knee arthros-
copy with symptoms of suspected articular cartilage, meniscal or
anterior cruciate ligament damage or degeneration.
RA synovia demonstrated classic RA histopathology with
thickening of the lining layer and mononuclear inﬁltration of the
sub-lining including formation of perivascular inﬁltrates. Non-RA
synovia were obtained from arthroscopically non-inﬂamed sites
and were histologically normal in appearance.2.3. Peripheral blood
Peripheral blood (PB) was obtained from RA patients with active
disease as deﬁned by raised ESR and CRP, n = 11 (2 male and 9 fe-
male; average age 61.9 years, range 38–94 years; disease duration
ranging from 6 months to 24 years) who were taking non-steroidal
anti-inﬂammatory drugs, disease modifying drugs or steroids. 4
patients were rheumatoid factor (RF) positive, 4 were RF negative
and 3 of unknown RF status. Control samples were obtained from
healthy donors with no inﬂammatory conditions, n = 11 (4 male
and 7 female; average age 51.8 years, range 28–78 years); 7 were
RF negative and 4 of unknown RF status.
2.4. Leukocyte isolation
Leukocytes were isolated from EDTA-treated PB by lysing the
erythrocytes for 15 min using an ice-cold isotonic solution of
ammonium chloride. The leukocytes were then collected by
centrifugation.
2.5. Monocyte/macrophage isolation
Healthy PB was collected into preservative-free heparin and
mononuclear cells were isolated by gradient centrifugation with
Ficoll-Paque Plus (Amersham-Biosciences, Little Chalfont, UK).
Monocytes/macrophages were further isolated by the standard
procedure of adherence onto a glass dish which was carried out
for 30–45 min at 37 C, 5% CO2 [19]. Non-adherent cells were
washed off leaving monocytes/macrophages which were then
lysed for RT-PCR.
2.6. Flow cytometry
Isolated leukocytes were analysed for cell surface expression of
chemokine receptors and cluster of differentiation (CD) markers by
ﬂow cytometry. Non-speciﬁc binding by Fc receptors was blocked
with 10% high purity human immunoglobulin (Flebogamma;
Grifols, Cambridge, UK Ltd.). Cells (3  105) were then stained for
30 min with antibody against chemokine receptors, CD markers
or isotype controls, with each primary antibody tested in a sepa-
rate tube. The antibodies used were anti-human GPR15/BOB
mouse monoclonal antibody (10 lg/ml, MAB3654; clone 367902;
R&D Systems, Abingdon, UK), anti-human CD14mouse monoclonal
antibody (5 lg/ml, 555396; BD Biosciences, Oxford, UK), anti-hu-
man CD3 mouse monoclonal antibody (15 lg/ml, M0835; Dako,
Ely, UK) and anti-human CXCR1 mouse monoclonal (25 lg/ml,
MAB330; R&D Systems) and isotype controls IgG1, IgG2a and
IgG2b (all from Dako), all in 2% bovine serum albumin (BSA)/phos-
phate buffered saline (PBS). After washing with 2%BSA/PBS, cells
were further incubated for 30 min with either goat anti-mouse
IgG2b-RPE (for GPR15/BOB), goat anti-mouse IgG2a-RPE (for
CD14 and CXCR1), or goat anti-mouse IgG-FITC (for CD3) second-
ary antibodies (all Cambridge Biosciences, Cambridge, UK). Follow-
ing washing samples were analysed on a FACScan ﬂow cytometer
with CellQuestPro software (Becton Dickinson, Oxford, UK). Leuko-
cyte populations were identiﬁed by their forward scatter (FSC) ver-
sus side scatter (SSC) proﬁles and by their strong expression of
CD14 (monocytes), CD3 (T cells) or CXCR1 (neutrophils).
2.7. Immunoﬂuorescence labelling of synovial tissue sections
Immunoﬂuorescence staining of synovial tissue cryosections
(6 lm thick) was performed with sections ﬁxed in acetone for
10 min on ice, rinsed in PBS and incubated for 1 h with anti-human
GPR15/BOB antibody (5 lg/ml; as above). For double label experi-
ments anti-GPR15/BOB antibody was incubated together with
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TÜK4), CD68 (9 lg/ml; clone EBM11), CD20 (2 lg/ml; clone L26),
CD3 (6 lg/ml; clone F7.2.38) (all from Dako) or CD138 (2 lg/ml;
clone B-A38; Serotec) all in PBS. Detection of anti-GPR15/BOB anti-
body was with Alexa 488 goat anti-mouse IgG2b. Antibodies to
CD14 and CD20 were detected with Alexa 594 goat anti-mouse
IgG2a and antibodies to CD68, CD3 and CD138 were detected with
Alexa 594 goat anti-mouse IgG1 secondary antibody. All secondary
antibodies (Molecular Probes, Invitrogen, Paisley, UK) were diluted
1:400 in PBS containing 10% human serum. Nuclear staining was
performed with 40,6-diamidino-2-phenylindole dihydrochloride
(DAPI; 2 lg/ml in PBS; Sigma, Poole, UK) for 3 min before mount-
ing. Controls were performed using isotype-matched IgGs (Dako)
in place of primary antibodies, followed by respective Alexa sec-
ondary antibodies.2.8. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from frozen blocks of synovia using
TRIreagent solution (Sigma, Poole, UK) or from isolated mono-
cytes/macrophages using RNAqueous kit (Ambion, Applied
Biosystems, Warrington, UK) according to the manufacturer’s
instructions. The quantity recovered was determined by spectro-
photometry and the integrity was assessed by agarose gel electro-
phoresis. Total RNA (1 lg) was reverse transcribed using oligo(dT)
primers (MWG Biotech, Ebersberg, Germany) and MMLV reverse
transcriptase (Promega, Southampton, UK) at 37 C for 1 h. The
reactions were then heated to 70 C for 5 min to inactivate the en-
zyme, placed on ice and 60 ll H2O was added. Appropriate dilu-
tions of the resulting cDNA were then used for semi-quantitative
PCR using speciﬁc primers for GPR15/BOB [F 50-GTG ATG GAC
CCA GAA GAA AC-30; R 50-GGA CAG AAG AGT AGG CAA CC-30
(515 base pairs (bp); GenBank:NM005290); MWG Biotech]. PCR
primers were run through a BLAST program to ensure gene speci-
ﬁcity. The PCR reactions were normalised against the ribosomal
RNA L27 using speciﬁc primers [F 50-GAC GCA AAG CTG TCA TCG
TG-30; R 50-GCA GTT TCT GGA AGA ACC AC-30 (344 bp; Gen-
Bank:BC007273); MWG Biotech]. The annealing temperature was
57 C for each primer pair.2.9. Statistical analysis
GraphPad Prism Version 5.01 was used for all statistical analy-
sis. Expression of GPR15/BOB protein was analysed on synovial
cryosections by unpaired t test. Levels of receptor protein (mean
ﬂuorescence intensities) on PB leukocytes were analysed by Mann
Whitney test and percentage positive PB leukocytes were analysed
by unpaired t test.3. Results
3.1. GPR15/BOB expression in synovium
Expression of GPR15/BOB was examined in synovial tissue
cryosections by immunoﬂuorescence staining. The receptor was
detected in all RA patients examined (n = 13) in both lining
(Fig. 1A) and sub-lining layers (Fig. 1B) where expression was gen-
erally strong, localising to the cell membrane and cytoplasm. The
proportion of stained cells varied between patients from a few
scattered positive cells to widespread positivity. By contrast, in
non-RA synovial sections (n = 9 individuals) weaker expression of
GPR15/BOB was observed in the lining layer (Fig. 1C) and was
essentially negative in the sub-lining. No staining was observed
using the isotype controls for all antibodies used (Fig. 1D).To identify the cell type expressing GPR15/BOB, double label
immunoﬂuorescence was carried out using antibodies to GPR15/
BOB and markers for monocytes/macrophages, T cells, B cells and
plasma cells; neutrophils are rarely present in synovial tissue
and were not examined [20]. GPR15/BOB was present on mono-
cytes/macrophages identiﬁed by the speciﬁc marker CD68
(Fig. 2A–C) in all RA synovia examined (CD68, n = 11). GPR15/
BOB co-localised with CD68 expression in the sub-lining and lining
layers. Non-RA synovia (n = 5) exhibited co-localisation of GPR15/
BOB with CD68 positive cells in the lining but not in the sub-lining
which was basically GPR15/BOB negative (Fig. 2D–F). CD14+ cells
also colocalised with GPR15/BOB and agreed with the CD68 results,
suggesting macrophages were positive for the receptor (data not
shown). No co-localisation was observed between GPR15/BOB
and CD3 (T lymphocytes) or CD20 (B lymphocytes) in either RA
or non-RA synovia (data not shown). Non-RA synovium demon-
strated limited staining with CD3 and occasional staining with
CD20. Co-localisation was effectively negative between GPR15/
BOB and CD138 (plasma cells) in RA synovia. Double labelling of
GPR15/BOB and CD138 was not carried out on non-RA tissue as
plasma cells are not present in non-inﬁltrated synovium. Tissue
sections stained with isotype controls in place of primary antibod-
ies were negative in each case (data not shown).
To quantitate the difference in expression of GPR15/BOB in RA
and non-RA synovia the number of GPR15/BOB+ and DAPI+ cells
were counted in the lining and sub-lining layers of both RA and
non-RA tissue (Fig. 3). The percentage of total cells (DAPI+) that ex-
pressed GPR15/BOB was signiﬁcantly higher in RA synovium in
comparison to non-RA in both the lining and sub-lining layers.3.2. GPR15/BOB expression by PB monocytes and neutrophils
GPR15/BOB expression by leukocytes from RA and healthy PB
was examined by ﬂow cytometry. Leukocyte populations were
identiﬁed by their FSC/SSC proﬁles and by their strong cell surface
expression of characteristic markers: CD14 on monocytes, CD3 on
T lymphocytes and CXCR1 on neutrophils. GPR15/BOB was
detected on monocytes and neutrophils (Fig. 4A). A signiﬁcant
increase in GPR15/BOB expression as measured by mean ﬂuores-
cence intensity (MFI) (Fig. 4B) was observed on RA PB neutrophils
and an increase close to signiﬁcance was observed on RA PB
monocytes when compared to these cell populations from healthy
donors. Furthermore a signiﬁcant increase in the percentage of
cells expressing GPR15/BOB was observed in RA neutrophil popu-
lations and also in RA monocyte populations (Fig. 4C). GPR15/
BOB was also detected on the surface of lymphocytes but expres-
sion was comparable between RA and healthy donors (data not
shown).3.3. RT-PCR analysis of GPR15/BOB
Expression of GPR15/BOB mRNA was analysed in RA (n = 8) and
non-RA (n = 7) synovia by RT-PCR to conﬁrm observations from
immunoﬂuorescence staining. GPR15/BOB mRNA was detected in
all RA patients examined although the band intensity varied be-
tween individuals (Fig. 5A), being considerably stronger in patients
2 and 8. GPR15/BOB mRNA was barely detectable in non-RA syno-
via, being detected in only one (patient 2) out of seven non-RA pa-
tients examined. L27 ribosomal gene was used to normalise PCR
reactions to allow comparison between samples.
To conﬁrm monocytes/macrophage expression of GPR15/BOB,
RT-PCR was performed on these cells isolated from the PB of
healthy donors (n = 9). GPR15/BOB mRNA was detected in isolated
monocytes/macrophages from these individuals (Fig. 5B).
Fig. 1. Expression of GPR15/BOB in RA and non-RA synovial tissue. Cryosections were incubated with antibody to GPR15/BOB and DAPI nuclear stain. The photomicrographs





Fig. 2. Expression of GPR15/BOB and CD68 in RA and non-RA synovium. Cryosections were stained with antibodies to GPR15/BOB and macrophage marker CD68. (A)
Rheumatoid synovial sub-lining stained with anti-GPR15/BOB (red), and (B) stained with anti-CD68 (green). (C) Merge of images (A) and (B) with DAPI displaying cells with
co-localised GPR15/BOB and CD68 (yellow). (D) Non-RA sub-lining stained with anti-GPR15/BOB (red) showing lack of expression, and (E) stained with anti-CD68 (green). (F)
Merge of images (D) and (E) with DAPI. The bar represents 50 lm.
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Inﬁltration of the synovial membrane by inﬂammatory leuko-
cytes is a characteristic pathological feature in rheumatoid arthritis
patients. Leukocytes including macrophages are recruited by the
action of chemoattractant cytokines secreted within the synovium
by both resident and inﬁltrated cells [4]. In this study we demon-
strated that the GPR15/BOB receptor was expressed by macro-
phages in synovial tissue with up-regulation in RA tissue. In
circulating blood both monocytes and neutrophils expressedGPR15/BOB. Percentages of GPR15/BOB+ cells were signiﬁcantly
raised in RA blood and the abundance of GPR15/BOB on these cells
was also greater in RA in comparison to healthy donor blood. This
suggests that in RA there may be preferential recruitment of
GPR15/BOB+ monocytes to the synovium or alternatively GPR15/
BOB may be up-regulated on monocytes, via the actions of pro-
inﬂammatory cytokines, once the monocytes have reached the
synovium.
Examination of synovial tissue mRNA expression suggested
GPR15/BOB was expressed in all RA patients examined. The mRNA
Fig. 3. Percentage GPR15/BOB positive cells in synovial lining and sub-lining from
RA and non-RA patients. The percentage (mean ± standard deviation) of total cells
(DAPI+) that expressed GPR15/BOB in the lining and sub-lining layers of RA (n = 4)
and non-RA tissue (n = 3) was signiﬁcantly higher in RA synovium in comparison to
non-RA in both the lining (p = 0.0003) and sub-lining layers (p = 0.0005) by
unpaired t test. Cells were counted in 5 randomly selected ﬁelds of view using
magniﬁcation of 600. *** = P < 0.001.
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which may be related to their elevated disease severity and ab-
sence of DMARD or steroid therapies. However, real-time PCR
would be needed to conﬁrm differences in GPR15/BOB expression
between RA patients.
GPR15/BOB mRNA was barely or not detected in non-RA syno-
vium. In addition, GPR15/BOB protein was detected at low level in
the synovial lining layer and was essentially negative in the sub-
lining. We have therefore shown that GPR15/BOB is up-regulated
in RA synovia compared to non-RA controls. A previous initialRA neutrophils RA monocytes
A
B
Fig. 4. GPR15/BOB expression by neutrophils and monocytes in RA peripheral blood
expression by neutrophil and monocyte populations (solid ﬁll), empty ﬁll histograms repr
ﬂuorescence intensity (MFI; mean with 95% conﬁdence interval) increased signiﬁcantly o
monocytes (p = 0.056) when compared to these cell populations from healthy donors. Dat
also exhibited a signiﬁcant increase in percentage of cells expressing GPR15/BOB (p = 0.03
donors. The data represent percentage means ± standard deviation and were analysed b
*=P < 0.05.study by our group using gene microarrays of synovial tissue
showed that GPR15/BOB mRNA expression was present in RA
and not detected in non-RA [17] and the results of the present
study are therefore in agreement with and extend this earlier
report.
Chemokine receptor expression is regulated as a result of signal
transduction cascades which occur following the ligation of cell
surface receptors by cytokines such as TNFa which are known to
increase in the circulation in RA [21]. The subsequent transcrip-
tional activation of genes involved in inﬂammation leads to
production of pro-inﬂammatory cytokines, chemokines and in-
creased expression of cell surface receptors. Therefore elevated
cytokines in RA may be up-regulating GPR15/BOB on monocytes/
macrophages and neutrophils. In this connection, expression of
CCR9 was found to increase signiﬁcantly on THP-1 monocytic cells
following TNFa stimulation [22].
Cell surface expression of GPR15/BOB may be induced by extra-
cellular signals that activate the PI3-kinase pathway and increase
binding of 14-3-3 (a scaffold protein involved in signaling complex
formation) to GPR15/BOB leading to its subsequent expression on
the cell-surface [23]. The increase in expression of GPR15/BOB on
monocytes in PB may be related to the increased expression of
GPR15/BOB in RA synovium in that PB monocytes bearing the
receptor may be recruited from the blood into the synovium in
RA, possibly involving an unknown ligand to GPR15/BOB.
GPR15/BOB is expressed by CD4+ T cells [7] and although PB
lymphocytes expressed GPR15/BOB in this study they were not po-
sitive in the synovium suggesting that GPR15/BOB+, CD4+ T cells
were not recruited to the synovium via a GPR15/BOB ligand. How-
ever, neutrophils bearing GPR15/BOB may be recruited into the RA
joint. Neutrophils are not present in the RA synovium to any appre-
ciable extent [24], but they are present in synovial ﬂuid and haveC
(PB) using ﬂow cytometry. (A) Representative histograms showing GPR15/BOB
esent the isotype-matched control. (B) GPR15/BOB expression as measured by mean
n RA PB neutrophils (p = 0.030) and with an increase close to signiﬁcance on RA PB
a were analysed by MannWhitney test. (C) RA neutrophil andmonocyte populations
5 and p = 0.034 respectively) when compared to these cell populations from healthy
y unpaired t tests. Data were from healthy donors (n = 11) and RA patients (n = 11).
GPR15
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Fig. 5. GPR15/BOB mRNA in synovial tissue and monocytes/macrophages by RT-PCR. (A) RNA isolated from synovial tissue of RA patients (n = 8) and non-RA controls (n = 7)
showing the presence of GPR15/BOB mRNA. (B) GPR15/BOB mRNA expression by monocytes/macrophages isolated from PB of healthy donors (n = 9). PCR reactions were
normalised using L27 ribosomal protein.
58 A. Cartwright et al. / Cytokine 67 (2014) 53–59been found to express GPR15/BOB in RA patients [unpublished
observation by Dr Caroline Schmutz]. Therefore increased expres-
sion of GPR15/BOB on PB neutrophils in RA may be involved in dis-
ease pathology.
Interestingly, SIV envelope-ligation of GPR15/BOB on the sur-
face of circulating neutrophils from Chinese rhesus macaques
was found to induce neutrophil apoptosis during SIV infection
[14]. HIV patients also suffer from increased neutrophil apoptosis
in chronic disease and the rate of neutrophil apoptosis and associ-
ated neutropenia is related to rate of disease progression [14]. A
role for GPR15/BOB in regulating neutrophil apoptosis in RA is cur-
rently unknown.
Macrophages play a major role in the pathogenesis of RA due
to their production of pro-inﬂammatory cytokines including TNFa
and IL-1b, inﬂammatory chemokines including CXCL8 and CCL2,
and also degradative enzymes. These factors all contribute to
synovial inﬂammation and joint erosion. Neutrophils accumulate
in the synovial ﬂuid in RA where they become activated, releasing
proteases and lysozomal enzymes leading to cartilage damage,
and also pro-inﬂammatory cytokines and chemokines including
IL-1, CXCL8 and CCL3 [25,26]. The GPR15/BOB receptor on mono-
cytes/macrophages and neutrophils may therefore play a role in
RA by attracting these cells into the synovial joint in response
to unknown ligand(s) to GPR15/BOB. Since macrophages are
important cells in RA pathology GPR15/BOB may provide an inter-
esting therapeutic target in the treatment of inﬂammation and
joint destruction in patients, and further work on the function
of this receptor in RA would be of interest. A recent study by
Kim et al. [16] has found the presence of GPR15/BOB on T cells,
especially FOXP3(+) regulatory T cells, which regulated homing
of these cells to the large intestine, leading to altered inﬂamma-
tion. In the current study GPR15/BOB was mainly expressed by
monocytes/macrophages in the RA synovium rather than T cells.
Therefore there may be tissue-speciﬁc differences in the expres-
sion and role of GPR15/BOB.Funding
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